Drug Safety During the COVID-19 Pandemic - Dr. Andrew Rut in Pharmaceutical Executive

Drug Safety During the COVID-19 Pandemic - Dr. Andrew Rut in Pharmaceutical Executive

News
14/04/20

In this Pharmaceutical Executive article, Dr. Andrew Rut discusses the importance of capturing robust data to assess the safety and efficacy of new treatments and vaccines for COVID-19. Dr Rut shares his views on the role of Large Simple Trials in understanding benefit-risk across broad populations given the potential impact of confounding factors such as preexisting conditions on drug safety and efficacy. Finally he discusses how digital technology can streamline drug safety reporting processes and transfer robust, accurate data direct to pharmacovigilance teams.

Read the full article 'What is Required of Drug Safety During the COVID-19 Pandemic?'.


Request More Information

To find out more or request a demo fill in the details below:


By submitting your information, you are consenting to receive communications from MyMeds&Me. You may at any time 'opt out' of receiving these marketing communications by emailing info@mymedsandme.com.

Keep informed

For expert insight and updates from the MyMeds&Me team.

We respect your privacy and we will only use your email address for newsletters and company updates